{
    "clinical_study": {
        "@rank": "109440", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator.  Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician."
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to compare the efficacy and safety of a new basal insulin,\n      insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM).\n      Both drugs will be given by an injection under the skin.  Participants may continue to take\n      oral antihyperglycemic medication (OAM) during the study, as prescribed by their personal\n      physician.  The study is expected to last about 12 months for each participant."
        }, 
        "brief_title": "A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have T2DM (per World Health Organization [WHO] Classification of Diabetes) not\n             treated with insulin.\n\n          -  Have had diabetes for at least 1 year.\n\n          -  Have been receiving at least 2 oral antihyperglycemic medications (OAMs) for at least\n             3 months prior to the study.\n\n          -  Have hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to central lab at\n             screening.\n\n          -  Have body mass index (BMI) \u226440 kilogram/square meter (kg/m^2).\n\n          -  This inclusion criterion applies to females of child-bearing potential (not\n             surgically sterilized and between menarche and 1-year postmenopausal) only: are not\n             breastfeeding, test negative for a serum pregnancy test, intend not to become\n             pregnant during study or willing to have a reliable method of birth control.\n\n        Exclusion Criteria:\n\n          -  Insulin therapy: have used insulin therapy (outside of pregnancy) anytime in the past\n             2 years, except for short-term treatment of acute conditions, and up to a maximum of\n             4 continuous weeks. Insulin use of any duration during pregnancy is not considered an\n             exclusion criterion.\n\n          -  Concomitant medications: rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1)\n             receptor agonist (for example, exenatide, exenatide once weekly, or liraglutide) used\n             concurrently or within 3 months prior to screening.\n\n          -  Local OAM restrictions: for participants on OAMs, restrictions for cardiac, renal,\n             hepatic diseases and maximum dose, local product regulations must apply.\n\n          -  Weight loss medications: are currently taking, or have taken within the 3 months\n             preceding screening, prescription or over-the-counter medications to promote weight\n             loss.\n\n          -  Severe hypoglycemia history: have had any episodes of severe hypoglycemia within 6\n             months prior to screening.\n\n          -  Diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar nonketotic coma (HHNKC):\n             have had 1 or more episodes of DKA or hyperosmolar state/coma in the past 6 months.\n\n          -  Cardiovascular: have cardiac disease with functional status that is New York Heart\n             Association Class III or IV (per New York Heart Association [NYHA] Cardiac Disease\n             Classification).\n\n          -  Renal: have a history of renal transplantation, or are currently receiving renal\n             dialysis or have serum creatinine \u22652 milligram/deciliter (mg/dL)  (177\n             micromole/liter [mol/L]).\n\n          -  Hepatic: have obvious clinical signs or symptoms of liver disease (excluding\n             non-alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic\n             steatohepatitis (NASH), or elevated liver enzyme measurements.\n\n          -  Lipid-lowering medications:\n\n               -  Are using niacin preparations as a lipid-lowering medication or bile acid\n                  sequestrants within 90 days prior to screening; or,\n\n               -  Are using lipid-lowering medication at a dose that has not been stable for \u226590\n                  days prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "663", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106364", 
            "org_study_id": "13564", 
            "secondary_id": "I2R-MC-BIDB"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY2605541", 
                "description": "Administered SQ", 
                "intervention_name": "Insulin Peglispro", 
                "intervention_type": "Drug", 
                "other_name": "LY2605541"
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "description": "Administered SQ", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India", 
                        "zip": "560 052"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Belgaum", 
                        "country": "India", 
                        "zip": "590 010"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hyderabaad", 
                        "country": "India", 
                        "zip": "500033"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Kochin", 
                        "country": "India", 
                        "zip": "682026"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India", 
                        "zip": "226003"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India", 
                        "zip": "400 008"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India", 
                        "zip": "411 011"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel", 
                        "zip": "25428"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Raanana", 
                        "country": "Israel", 
                        "zip": "43452"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Rishon Le Zion", 
                        "country": "Israel", 
                        "zip": "75650"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Benoni", 
                        "country": "South Africa", 
                        "zip": "1501"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Durban", 
                        "country": "South Africa", 
                        "zip": "4091"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Somerset West", 
                        "country": "South Africa", 
                        "zip": "7130"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Changhua", 
                        "country": "Taiwan", 
                        "zip": "500"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Kaohsiung", 
                        "country": "Taiwan", 
                        "zip": "824"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Niao Sung Hsiang", 
                        "country": "Taiwan", 
                        "zip": "833"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung City", 
                        "country": "Taiwan", 
                        "zip": "40201"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "India", 
                "Israel", 
                "South Africa", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Na\u00efve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Israel: Ethics Commission", 
                "India: Ministry of Health", 
                "China: Food and Drug Administration", 
                "Taiwan : Food and Drug Administration", 
                "South Africa: Medicines Control Council"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Hemoglobin A1c (HbA1c)  at 26 Week Endpoint", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 26 Weeks"
        }, 
        "removed_countries": {
            "country": "China"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106364"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of Participants with HbA1c \u22646.5% and <7.0%", 
                "safety_issue": "No", 
                "time_frame": "Week 26 and Week 52"
            }, 
            {
                "measure": "Proportion of Participants with HbA1c <7.0% Without Nocturnal Hypoglycemia Event", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 26 Weeks and Baseline through 52 Weeks"
            }, 
            {
                "measure": "Rate of Total and Nocturnal Hypoglycemia Events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Fasting Serum Glucose (FSG) by Laboratory Measurements", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "9 Point Self Monitored Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Body Weight at Week 26 Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "Change from Baseline in HbA1c at 52 Week Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 52"
            }, 
            {
                "measure": "Insulin Dose by Unit", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Time to Reach Steady-State", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 52 Weeks"
            }, 
            {
                "measure": "Fasting Blood Glucose by Self Monitoring", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 52 Weeks"
            }, 
            {
                "measure": "Intra-Participant Variability in Fasting Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 52 Weeks"
            }, 
            {
                "measure": "Change from Baseline in EuroQol-5 Dimension Questionnaire (EQ-5D) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26, Week 52"
            }, 
            {
                "measure": "Change from Baseline in the Low Blood Sugar Survey (LBSS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26, Week 52"
            }, 
            {
                "measure": "Number of Participants Developing Anti-Insulin Peglispro Antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Week 26 and Week 52"
            }, 
            {
                "measure": "Change from Baseline in Lipid Profile", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 26"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}